BRCA1-BRCA2 mutation analysis results in 910 individuals: Mutation distribution and 8 novel mutations


      • BRCA1/2 mutations detected nearly 10 percent of the patients who underwent testing.
      • Family history and age of diagnosis are the most important risk factors for BRCA1/2 mutation.
      • Sequencing analysis of large exons (BRCA1-exon 10, BRCA2-exon 11) could detect more than half of mutations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA. Cancer J. Clin. 2017;
        • Claus E.B.
        • Risch N.
        • Thompson W.D.
        Genetic analysis of breast cancer in the cancer and steroid hormone study.
        Am. J. Hum. Genet. 1991;
        • Lux M.P.
        • Fasching P.A.
        • Beckmann M.W.
        Hereditary breast and ovarian cancer: review and future perspectives.
        J. Mol. Med. 2006;
        • Miki Y.
        • Swensen J.
        • Shattuck-Eidens D.
        • Futreal P.A.
        • Harshman K.
        • Tavtigian S.
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; (80-.)
        • Wooster R.
        • Bignell G.
        • Lancaster J.
        • Swift S.
        • Seal S.
        • Mangion J.
        • et al.
        Identification of the breast cancer susceptibility gene BRCA2.
        Nature. 1995;
        • Mavaddat N.
        • Antoniou A.C.
        • Easton D.F.
        • Garcia-Closas M.
        Genetic susceptibility to breast cancer.
        Mol. Oncol. 2010;
        • Gabai-Kapara E.
        • Lahad A.
        • Kaufman B.
        • Friedman E.
        • Segev S.
        • Renbaum P.
        • et al.
        Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
        Proc. Natl. Acad. Sci. 2014;
        • Brose M.S.
        Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.
        CancerSpectrum Knowl. Environ. 2002;
        • The Breast Cancer Linkage Consortium
        Cancer Risks in BRCA2 Mutation Carriers.
        JNCI J. Natl. Cancer Inst. 1999;
        • Kang E.
        • Seong M.W.
        • Park S.K.
        • Lee J.W.
        • Lee J.
        • Kim L.S.
        • et al.
        The prevalence and spectrum of BRCA1 and BRCA2 mutations in Korean population: recent update of the Korean Hereditary Breast Cancer (KOHBRA) study.
        Breast Cancer Res. Treat. 2015; 151: 157-168
        • Finch A.P.M.
        • Lubinski J.
        • Møller P.
        • Singer C.F.
        • Karlan B.
        • Senter L.
        • et al.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J. Clin. Oncol. 2014;
        • Lostumbo L.
        • Carbine N.E.
        • Wallace J.
        Prophylactic mastectomy for the prevention of breast cancer.
        in: Cochrane Database Syst. Rev.2010
        • Wang F.
        • Fang Q.
        • Ge Z.
        • Yu N.
        • Xu S.
        • Fan X.
        Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.
        Mol. Biol. Rep. 2012;
        • Daly M.B.
        • Pilarski R.
        • Axilbund J.E.
        • Berry M.
        • Buys S.S.
        • Crawford B.
        • et al.
        Genetic/familial high-risk assessment: breast and ovarian, version 2.2015.
        J. Natl. Compr. Cancer Netw. 2016;
        • Yazici H.
        • Bitisik O.
        • Akisik E.
        • Cabioglu N.
        • Saip P.
        • Muslumanoglu M.
        • et al.
        BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients.
        Br. J. Cancer. 2000; 83: 737-742
      1. Yazıcı H, Frequency of rearrangements versus small indels mutations in BRCA1 and BRCA2 genes in Turkish patients with high risk breast and ovarian cancer, (2018) 93–-99. doi:10.5152/ejbh.2017.3799.

        • Szabo C.I.
        • King M.C.
        Population genetics of BRCA1 and BRCA2.
        Am J Hum Genet. 1997; (doi:papers2://publication/uuid/3E108D68-23A1-44A7-9F56-3D1C35A0FF2D)
        • Dodova R.I.
        • Mitkova A.V.
        • Dacheva D.R.
        • Hadjo L.B.
        • Vlahova A.I.
        • Hadjieva M.S.T.
        • et al.
        Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
        BMC Cancer. 2015; : 15
        • Janavičius R.
        Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
        EPMA J. 2010; 1: 397-412
        • Manguoĝlu E.
        • Güran Ş.
        • Yamaç D.
        • Çolak T.
        • Şimşek M.
        • Baykara M.
        • et al.
        Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
        Cancer Genet. Cytogenet. 2010; 203: 230-237
        • Cecener G.
        • Egeli U.
        • Tunca B.
        • Erturk E.
        • Ak S.
        • Gokgoz S.
        • et al.
        BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
        Cancer Invest. 2014; 32: 375-387
        • Özdag H.
        • Tez M.
        • Sayek I.
        • Müslümanoglu M.
        • Tarcan O.
        • Içli F.
        • et al.
        Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients.
        Eur. J. Cancer. 2000;
        • Goidescu I.G.
        • Caracostea G.
        • Eniu D.T.
        • Stamatian F.V.
        Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population.
        Clujul Med. 2018;
        • Apessos A.
        • Agiannitopoulos K.
        • Pepe G.
        • Tsaousis G.N.
        • Papadopoulou E.
        • Metaxa-Mariatou V.
        • et al.
        Comprehensive BRCA mutation analysis in the Greek population. Experience from a single clinical diagnostic center.
        Cancer Genet. 2018; 220: 1-12
        • Kim B.Y.
        • Lee D.G.
        • Lee K.R.
        • Han S.H.
        • Surendran S.
        • Han C.W.
        • et al.
        Identification of BRCA1 and BRCA2 mutations from Korean breast cancer patients using denaturing HPLC.
        Biochem. Biophys. Res. Commun. 2006;
        • Kim H.
        • Cho D.Y.
        • Choi D.H.
        • Choi S.Y.
        • Shin I.
        • Park W.
        • et al.
        Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3922 Korean patients with breast and ovarian cancer.
        Breast Cancer Res. Treat. 2012;
        • Szwiec M.
        • Jakubowska A.
        • Górski B.
        • Huzarski T.
        • Tomiczek-Szwiec J.
        • Gronwald J.
        • et al.
        Recurrent mutations of BRCA1 and BRCA2 in Poland: An update.
        Clin. Genet. 2015;
      2. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, et al., Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study, 1998. (accessed January 22, 2019).

      3. Infante M, Duran M, Acedo A, Sanchez-Tapia EM, Diez-Gomez B, Barroso A, et al., The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins, Carcinogenesis. 34 (2013) 2505–2511. doi:10.1093/carcin/bgt272.

        • Yazici H.
        • Glendon G.
        • Yazici H.
        • Burnie S.J.
        • Saip P.
        • Buyru F.
        • et al.
        BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: A high incidence of mutations in non-familial cases.
        Hum. Mutat. 2002; 20: 28-34
        • Pal T.
        • Bonner D.
        • Cragun D.
        • Johnson S.
        • Akbari M.
        • Servais L.
        • et al.
        BRCA sequencing and large rearrangement testing in young Black women with breast cancer.
        J. Community Genet. 2014;
        • Balci A.
        • Huusko P.
        • Pääkkönen K.
        • Launonen V.
        • Uner A.
        • Ekmekçi A.
        • et al.
        Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
        Eur. J. Cancer. 1999; 35: 707-710
        • Bonatti F.
        • Pepe C.
        • Tancredi M.
        • Lombardi G.
        • Aretini P.
        • Sensi E.
        • et al.
        RNA-based analysis of BRCA1 and BRCA2 gene alterations.
        Cancer Genet. Cytogenet. 2006; 170: 93-101
        • Karami F.M.
        A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.
        Biomed Res. Int. 2013; 201928562
        • Nanda R.
        • Schumm L.P.
        • Cummings S.
        • Fackenthal J.D.
        • Sveen L.
        • Ademuyiwa F.
        • et al.
        Genetic testing in an ethnically diverse cohort of high-risk women.
        JAMA. 2005; 294: 1925
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • Phillips K.A.
        • Mooij T.M.
        • Roos-Blom M.J.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA - J. Am. Med. Assoc. 2017;